Navigation Links
ReportsandReports: Biosimilars Series - Forecast Analysis Market Research Report

DALLAS, Texas, February 2 /PRNewswire/ -- ReportsandReports announce to have Biosimilars Series: Forecast Analysis ( Analysis/) Market Research Report in its store

The high cost and utilization of biologic drugs, coupled to the growing need to curb pharmaceutical expenditure, provides considerable momentum to the emerging biosimilars market. With a biosimilar approval pathway in place in Europe and Japan, and imminently in the US, Datamonitor expects payer pressure to drive biosimilar uptake, particularly in Germany, the US, and the UK.


    - Molecule-specific forecasts for biosimilar epoetin alpha, filgrastim,
      interferon beta, interferon alpha, human growth hormone, and

    - Molecule-specific forecasts for France, Germany, Italy, Spain, the US,
      and Japan through 2019.

    - An overview of the emerging biosimilars market, including a regulatory

    - An outline of the key issues which will impact on biosimilars uptake
      going forward.


As the first to introduce guidelines for biosimilar drug approval, Europe has emerged as the testing ground for biosimilar drugs, with biosimilars for three biologics having entered the market to date human growth hormone, epoetin alpha, and filgrastim.

The size of the US market, combined with the voracious generic erosion that characterize it, make it an attractive prospect for would-be biosimilars makers, and as such, it represents the real prize, contingent on the creation of a biosimilars approval pathway.

Although guidance for biosimilar approval was issued in Japan in 2009, this market is unlikely to experience significant biosimilar incursion through the forecast period, contributing at most 1% to total seven major market volume sales in 2019.

    Reasons to Purchase

    - Learn how biosimilar uptake for six biologic drugs is anticipated to
      change through 2019, in France, Germany, Italy, Spain, the UK, the US,
      and Japan.

    - Understand how the seven major markets compare in terms of speed and
      extent of biosimilars uptake.

    - Identify the key molecule and market specific drivers and resistors to
      biosimilar uptake.

Related Reports

HVAC in the U.S., 2nd Edition - Green and Global ( 2%80%94-green-and-global/)

Global Biomaterial Market (2009-2014) ( 9-2014/)

World Market for Biosimilars and the Potential for US Followon Biologics ( -and-the-potential-for-us-followon-bi/)

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser's URL address field. Remove the space if one exists.)


    Ms. Sunita
    7557 Rambler road,
    Suite 727, Dallas, TX 75231
    Tel: +1-888-989-8004

SOURCE MarketsandMarkets

SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Globus Medical Raises $110 Million in Series E Financing Round
2. BioVascular Inc. Closes $10.87 Million Series C Financing
3. PG500 Series Presented at the AACR Annual Meeting in San Diego
4. Light Sciences Oncology Raises $40.1 Million in Series C Financing
5. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
6. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
7. Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments
8. Lutonix Inc. Announces $20 Million Series B Financing
9. Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series
10. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
11. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):